Addictions Treatment and Rehab Centres in Plymouth

AddictionAdvisor^TM is a professional addictions healthcare company focused on providing you with high quality expert advice, information, care planning and treatment for addiction problems, wherever you live in the UK.

All advice is provided completely free-of-charge by our expert assessment team.  Led by a consultant addiction psychiatrist, the assessment team consists of nurses, doctors, counsellors and psychologists who work together to bring you the best advice, treatment and value available.

Addictions Rehab Centres in Plymouth

Call 0845 370 0102 Now for Full Details

Addictions Advisor's highly trained professionals can give you advice on which addiction treatment center is most appropriate for your need. This is done based on clinical need. Unlike various non-professional rehab ‘referral agents’ operating on the internet, all Addiction Advisor advice is provided by a highly qualified assessment team which specializes in considering the full range of treatment options available.

The website DryOutNow.com has specific information on alcohol treatment and alcoholism in the south west of England.

Addictions information

Novel compound shows promise for treatment of alcoholism

Southern Research Institute and Gallo Research Center recently announced that peer-reviewed results from a study testing Naltrexone-derived pyridomorphinan (SoRI-9409) will be published in the December 2008 issue of the journal Biological Psychiatry. The publication is available online now at the journal's website, and suggests that a new compound that causes selective and long-lasting reduction in ethanol consumption might be a promising candidate as a novel treatment for alcoholism.

The article presents the effects of SoRI-9409 on ethanol consumption. These are promising developments for the treatment of alcoholism. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) estimates 15.1 million people are alcohol-abusing or alcohol-dependent individuals. There are currently only three FDA-approved options for the treatment of alcoholism.

The compound, SoRI-9409, was first designed and synthesised in Southern Research's Drug Discovery research division by Dr. Subramaniam (Sam) Ananthan under U.S. Government Grant DA008883. "Southern Research has been particularly interested in ligands that interact with opioid delta receptor subtype since such ligands hold promise as therapeutic agents for treatment of drug addictions and other disorders," said Dr. Ananthan, senior scientist and manager of Computational Chemistry and CNS Discovery Chemistry at Southern Research Institute. "The present findings by Dr. Bartlett and her group on the effect of SoRI-9409 on its ability to reduce alcohol intake not only provides us with a new drug lead, but also serves as the impetus for further research aimed at discovery of new therapeutic compounds for treating alcoholism and related disorders."

The Preclinical Development Group that Dr. Bartlett leads at the UCSF-affiliated Gallo Center was established to develop new treatments and bridge the gap between research and clinical treatment. The purpose of the study was to find improved compounds for the treatment of alcoholism. "The study results demonstrate that this compound causes selective and long-lasting reductions of ethanol consumption and suggests the compound might be a promising candidate as a novel treatment for alcoholism. This study indicates that compounds with a higher affinity for delta opioid receptors and reduced affinity for mu opioid receptors might be better treatment candidates than Naltrexone, the current FDA approved treatment for alcoholism", said Dr. Bartlett.

"The study on SoRI-9409 and alcohol cessation has yielded vital data that will help fuel novel treatments for a devastating and very difficult-to-treat illness," said Dr. Bartlett. "To date, we have considered and evaluated other compounds, and theories, but the information yielded from this study, along with previous research on this particular compound, has proven to be the most promising to date. We are looking forward to collaborating with our partner, Southern Research, to enter the next phase of research."

First author on the paper is Carsten Nielsen, PhD, a postdoctoral scientist working with Bartlett. Co-authors are Jeffrey A. Simms, Haley B. Pierson, Rui Li at the Gallo Clinic and Research Center and Surendra K. Saini and Subramaniam (Sam) Ananthan at Southern Research Institute.

Reference

Nielsen et al., A Novel Delta Opioid Receptor Antagonist, SoRI-9409, Produces a Selective and Long-Lasting Decrease in Ethanol Consumption in Heavy-Drinking Rats', Biological Psychiatry, to be published in December 2008.

Article originally published on 14/09/2008 by DryOutNow.com, the alcohol specific website for Addiction Advisor.

DryOutNow.com specialises in alcohol help for those in Plymouth and Addictions Advisor handles all types of addiction for those in Plymouth .